[1]牛 奔,刘玺鲲,柴语鹃,等.全国药品集采中标药品和中选企业异常探测[J].卫生经济研究,2025,42(03):55-58.
　NIU Ben,LIU Xikun,CHAI Yujuan,et al.Detecting the Abnormalities of the Selected Drugs and Enterprises in National Centralized Procurement of Drugs[J].Journal Press of Health Economics Research,2025,42(03):55-58.
点击复制

全国药品集采中标药品和中选企业异常探测

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年03期
页码:
55-58
栏目:
药械管理
出版日期:
2025-03-04

文章信息/Info

Title:
Detecting the Abnormalities of the Selected Drugs and Enterprises in National Centralized Procurement of Drugs
作者:
牛 奔1; 2; 刘玺鲲1; 2; 柴语鹃2; 3; 蚁文洁1; 2
1.深圳大学管理学院，广东 深圳 518060
2.深圳大学大湾区国际创新学院，广东 深圳 518060
3.深圳大学医学部生物医学工程学院，广东 深圳 518060
Author(s):
NIU Ben;  LIU Xikun;  CHAI Yujuan;  YI Wenjie
School of Management, Shenzhen University, Shenzhen Guangdong 518060, China
关键词:
药品集中带量采购; “0-1”规划模型; 中标药品; 中选企业; 异常探测
Keywords:
centralized volume-based procurement;  "0-1" planning model;  selected drugs;  selected enterprises;  detection of abnormal situations
分类号:
R95
文献标志码:
A
摘要:
第九批全国药品集中带量采购共有41种中标药品，其中国家首年支付总额实际值与理想值差额处于异常值范围和临界值范围的各有5种；处于异常值范围的5种中标药品对应的中选企业共30家，其中首年销售额实际值与理想值的差额处于异常值范围的有14家。对此，可通过构建“0-1”规划模型，加强对中标药品和中选企业的异常探测，对不同支付额范围的中标药品实施差异化监管策略，多部门协调联动，确保全国药品集采的高度公平、透明与合规，在保障公众利益的同时，提升医疗保障体系的整体效能。
Abstract:
There are 41 selected drugs in the ninth batch of national centralized volume-based procurement of drugs, among which 5 of them are in the range of outliers and 5 of them are in the range of critical values in terms of the difference between the actual and ideal payment amounts in the first year. There are 30 selected enterprises corresponding to the 5 selected drugs in the range of outliers, and 14 of them are in the range of outliers. In this regard, the "0-1" planning model should be constructed to strengthen the detection of abnormal situations in the selected drugs and enterprises, implement differentiated supervision strategies for the selected drugs with different payment ranges, and coordinate and linkage among multiple departments to ensure the high degree of fairness, transparency and compliance of national centralized procurement of drugs. While safeguarding the public interest, the overall effectiveness of the medical security system has been improved.

参考文献/References:

[1] 谭清立，高江源，林岱衡.药品集中带量采购政策与我国医保支付制度的协同作用探讨[J].中国药房，2021，32（02）：146-151.
[2] 谭清立，陈洁颖.基于SWOT分析法的药品带量采购政策研究[J].中国卫生事业管理，2020，37（12）：910-912，948.
[3] 谭清立，郭润镒，孙慧琳，等.药品集中带量采购与医保谈判政策的协同作用[J].中国药房，2021，32（15）：1793-1799.
[4] 于培明，宋丽丽，岳淑梅.我国药品集中招标采购存在的制度缺陷[J].中国药物经济学，2010（04）：51-56.
[5] 顾海，唐艳，邓晨珂.我国药品集中招标采购制度的缺陷和对策[J].卫生经济研究，2006（07）：28-29.
[6] 朱恒鹏，岳阳，朱磊.药企合谋对药品招标采购的影响——以药品集中带量采购为例[J].经济学（季刊），2022，22（06）：2171-2192.
[7] 陈艳.从几个案例解析围标串标行为的成因和对策[J].技术与市场，2013，20（06）：225-226，228.
[8] 许金鹏，康正，石淇，等.面向公共价值创造的医保基金数字监管模型构建研究[J].中国医院管理，2024，44（04）：18-22.

相似文献/References:

[1]周 苑,汤质如,刘守明,等.药品集中采购模式研究及问题探讨[J].卫生经济研究,2018,(03):26.
[2]李 萍,汤少梁.后疫情时代药品集中带量采购政策制约因素与执行路径——基于史密斯政策执行模型[J].卫生经济研究,2021,38(4):32.
　LI Ping,TANG Shao-liang.The Restrictive Factors and Implementation Path of Drug Centralized Quantity Purchase Policy in the Post-epidemic Era——Based on Smith Policy Implementation Model[J].Journal Press of Health Economics Research,2021,38(03):32.
[3]任延峰,杨 毅,明 坚,等.药品集中采购政策的WHO经验及启示[J].卫生经济研究,2022,39(6):17.
　REN Yanfeng,YANG Yi,MING Jian,et al.Experience of WHO about Volume-Based Drug Procurement Policy[J].Journal Press of Health Economics Research,2022,39(03):17.
[4]郭 丽,王 健,王敬毅,等.药品集中采购政策对医院抗菌药物使用的影响研究[J].卫生经济研究,2022,39(6):24.
　GUO Li,WANG Jian,WANG Jingyi,et al.Effects of Volume-Based Procurement Policy on the Use of Antibiotics in Public Hospital[J].Journal Press of Health Economics Research,2022,39(03):24.
[5]周广进,常 峰,路 云.我国中成药集中带量采购政策研究[J].卫生经济研究,2023,40(6):18.
　ZHOU Guangjin,CHANG Feng,LU Yun.Study on the Policy of Centralized Volume-based Procurement of Chinese Patent Medicine in China[J].Journal Press of Health Economics Research,2023,40(03):18.
[6]马枋婷,常 峰,路 云,等.我国药品集中带量采购政策执行情况分析[J].卫生经济研究,2023,40(7):17.
　MA Fangting,CHANG Feng,LU Yun,et al.Analysis of the Implementation of National Centralized Drug Procurement Policy in China[J].Journal Press of Health Economics Research,2023,40(03):17.
[7]刘玉新,莫颖宁,郭德第.药品集中带量采购政策执行现状与接续建议——基于史密斯政策执行模型[J].卫生经济研究,2023,40(7):20.
　LIU Yuxin,MO Yingning,GUO Dedi.Implementation Situation and Continuation Suggestions of the Policy of Centralized Volume-based Procurement of Drugs ——Based on Smith Policy Implementation Process Model[J].Journal Press of Health Economics Research,2023,40(03):20.
[8]王 彪,廖 鹏,唐啸宇,等.国家集中带量采购中选药品的供应短缺问题研究[J].卫生经济研究,2024,41(02):40.
　WANG Biao,LIAO Peng,TANG Xiaoyu,et al.Study on the Supply Shortage of Selected Drugs in National Centralized Volume-based Procurement[J].Journal Press of Health Economics Research,2024,41(03):40.
[9]段凤然,文小桐,王 越,等.集采政策对医疗机构心血管药品采购的影响研究[J].卫生经济研究,2024,41(03):69.
　DUAN Fengran,WEN Xiaotong,WANG Yue,et al.Study on the Impact of Centralized Volume-based Procurement Policy on the Procurement of Cardiovascular Drugs in Medical Institutions[J].Journal Press of Health Economics Research,2024,41(03):69.
[10]宋 菲,陈 昊,王晨舟,等.国家药品集采对儿童用药供应保障的影响分析[J].卫生经济研究,2024,41(10):10.
　SONG Fei,CHEN Hao,WANG Chenzhou,et al.Analysis of the Impact of National Centralized Volume-based Procurement of Drugs on the Supply Guarantee of Children's Drugs[J].Journal Press of Health Economics Research,2024,41(03):10.

更新日期/Last Update: 2025-03-04